UMB Data Catalog

A project of the Health Sciences and Human Services Library
Find Datasets from
UMB Researchers
Include your dataset
of 1 Next >
Results Found: 3

  • GISAID

    Alternate Title(s)
    Global Initiative on Sharing All Influenza Data
    Description

    "The GISAID Initiative promotes the rapid sharing of data from all influenza viruses and the coronavirus causing COVID-19. This includes genetic sequence and related clinical and epidemiological data associated with human viruses, and geographical as well as species-specific data associated with avian and other animal viruses, to help researchers understand how viruses evolve and spread during epidemics and pandemics. GISAID does so by overcoming disincentive hurdles and restrictions, which discourage or prevented sharing of virological data prior to formal publication." (From "Mission")

    Subject
    COVID-19
    Influenza in Birds
    Influenza, Human
    Geographic Coverage
    International
    Access Rights
    Unrestricted access
    Local Experts
    Davide Zella
    Francesca Benedetti
    Robert C. Gallo

  • mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
    UMB Dataset

    Authors
    Etsuro Nanishi
    Marisa E. McGrath
    Timothy R. O’Meara
    Soumik Barman
    17 more author(s)...
    Description

    This study investigates multiple vaccine strategies to enhance immunogenicity and protection against SARS-CoV-2 in aged mice. The study aims to determine the effect of a booster dose, with an emphasis on older age. Female three and eleven-month-old BALB/c mice were studied over the course of 38 weeks. Mice received BNT162b2 SARS-CoV-2 spike mRNA vaccine series, primary vaccination series, and mock Phosphate-buffered saline (PBS) injections. Single mouse experiments aimed to include 20 mice per group. Sample size and age criteria were chosen empirically based on the results of previous studies. Mice were randomly assigned to different treatment groups.

    Subject
    COVID-19/prevention & control
    Viral Vaccines/genetics
    Access Rights
    Unrestricted access
    Local Experts
    Matthew B. Frieman

  • Kinetics of SARS-CoV-2 antibody responses preCOVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case–control study
    UMB Dataset

    Authors
    Magali J. Fontaine
    Matthew N. Klein
    Elizabeth Wenqian Wang
    Paul Zimand
    8 more author(s)...
    Description

    This observational retrospective control study investigated the development of the humoral immune response to SARS-CoV-2 in convalescent plasma (CCP) recipients (n=34) and compared it to the humoral response in a group of patients not treated with CCP (n=68). Additionally, a separate comparison of clinical outcomes was performed between CCP recipients and a matched control group of untreated patients (n=34). Patients considered for enrollment in the study presented with severe COVID-19 and were hospitalized in the intensive care units (ICU) of 3 Maryland hospitals. Participants received a single unit of ABO compatible CCP of approximately 250mL. Blood samples for SARS-CoV-2 antibody titre measurements were collected immediately pre-transfusion (day 0) and on days 3, 7 and 14 post-transfusion. Non-transfused patients were used for comparison of antibody titres. Sample draws from this cohort ranged from 0 to 48 days after the onset of symptoms, which varied in severity. Non-transfused patients used for the clinical outcome analysis were matched to CCP recipients based on sex, age, and on three levels of respiratory support requirement (non-ventilated, mechanically ventilated and ventilated with extracorporeal membrane oxygenation (ECMO)) and were admitted in the same hospital. This dataset includes clinical variables from all transfused and non-transfused participants including: symptoms at presentation, level of respiratory support (mechanical ventilation/ECMO status), comorbidities, other SARS-CoV-2 directed therapies, 30-days in-hospital mortality, number of days on mechanical ventilation, number of days on ECMO support, ICU length of stay (LOS) and hospital LOS. Clinical improvement was assessed primarily on survival at 30 days. Secondary outcomes included the number of days on ventilatory and/or ECMO respiratory support, LOS in the hospital and LOS in the ICU.

    Subject
    COVID-19
    Immunization, Passive
    Geographic Coverage
    Maryland
    Timeframe
    2020
    Access Rights
    Approval required